UAB CFRC Administrative Core
UAB CFRC 行政核心
基本信息
- 批准号:10673354
- 负责人:
- 金额:$ 13.96万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2007
- 资助国家:美国
- 起止时间:2007-04-01 至 2028-04-30
- 项目状态:未结题
- 来源:
- 关键词:AccelerationAdvisory CommitteesAreaBiochemistryBiomedical ResearchBreast Fibrocystic DiseaseBusinessesCOVID-19Career MobilityCellsClinical SciencesCollaborationsCommunicationCommunitiesCore FacilityCystic FibrosisCystic Fibrosis Transmembrane Conductance RegulatorDevelopmentDiabetes MellitusDiseaseEnsureEnvironmentEquipmentEvaluationEvolutionFacultyFosteringFoundationsFundingGoalsGrantGrowthHuman ResourcesInstitutionInterdisciplinary StudyInvestmentsLeadershipMedicineMolecular GeneticsMonitorMusNational Institute of Diabetes and Digestive and Kidney DiseasesNewsletterObesityParticipantPediatricsPositioning AttributeProceduresProductivityProgram DevelopmentRattusRecommendationResearchResearch PersonnelResourcesScienceScientistSiteSite VisitSystemTechnologyTrainingTranslational ResearchTranslationsUnited States National Institutes of HealthUtilization ReviewWritingbasecareer developmentclinical centerdrug developmentequipment acquisitionexperiencegene therapygenetic technologyinnovationinnovative technologiesinventionmeetingsmembermucus clearancenext generationnovelnutritionoperationpandemic diseaseprogramsresearch and developmentskillssuccesssymposiumsynergismweb site
项目摘要
PROJECT SUMMARY/ABSTRACT
The UAB Cystic Fibrosis Research and Translation Core Center Administrative Core is responsible for the
overall administration and coordination of the Biomedical Research Cores, Pilot & Feasibility Program, and
Enrichment Program. The Administrative Core is directed by Drs. Bedwell (P30 Director) Birket, and Solomon
(Associate Directors), along with continued involvement from Dr. Rowe (Associate Director) that additionally
serves to assure a seamless partnership with initiatives from the CF Foundation. Dr. Guimbellot will serve as
Co-Director of the Enrichment Program with Dr. Birket. Under this leadership, with assistance from the
experienced Research Management and Administrative Team (including Mr. Jeffrey Allison, Center
Administrative Director, and Dr. Emily Falk-Libby, Program Director-Scientific Affairs), the Core will continue to
successfully support CF Center goals in the upcoming funding cycle by: 1) Establishing the overall scientific
direction of the UAB P30 CF Center and ensuring continued contributions and growth into the most relevant
disease areas, including application of genetic therapies (e.g., directing communications between the
Administrative Core, P30 investigators, members of the Center’s active Internal Advisory Board, and/or
external consultants on its External Advisory Board to review Center activities and identify research directions
and opportunities), 2) Facilitating the objectives of all P30 components (e.g., prioritizing Core resources and
new equipment acquisition for optimal utilization, overseeing new state-of-the-art Core research space and
facilities, coordinating training and professional development activities, maintaining a Center website,
overseeing membership, building the Biomedical Core research base and monitoring its productivity,
supporting internal and external collaborations, managing successful operations in COVID-19), and 3)
Integrating P30 components with other UAB NIH Centers (e.g., promoting and sharing its innovative resources
and communicating with other Center leadership such as the Center for Clinical and Translational Science
(UAB’s CTSA site), NIDDK-Diabetes Research and Training Center, NIDDK-Nutrition Obesity Research
Center, and NIDDK-Hepatorenal Fibrocystic Diseases Core Center) to identify continued opportunities for
multidisciplinary collaboration. In addition, specifically in support of the Center’s Enrichment and Pilot &
Feasibility Programs, the Administrative Core will continue to identify and integrate resources offered through
the Institution to maximize trainee success and transition to independence for junior faculty as well as to apply
its established, robust mechanisms for solicitation, review, and oversight of P30 pilot applications to foster new
and important contributions to CF science. Overall, it is the goal of the Administrative Core to optimally
promote synergy and progress within the CF P30 Center.
项目总结/文摘
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
David M. Bedwell其他文献
Long-term nonsense suppression therapy with NB84 moderates MPS IH disease progression
- DOI:
10.1016/j.ymgme.2013.12.106 - 发表时间:
2014-02-01 - 期刊:
- 影响因子:
- 作者:
Gwendolyn G. Gunn;Yanying Dai;Ming Du;Valery Beklakhov;Jeyakumar Kandasamy;Trenton R. Schoeb;Timor Baasov;David M. Bedwell;Kim M. Keeling - 通讯作者:
Kim M. Keeling
The nonsense suppression drug PTC124 restored alpha-<span class="small-caps">l</span>-iduronidase activity and reduces glycosaminoglycan accumulation in MPS IH mice carrying the Idua-W402X mutation
- DOI:
10.1016/j.ymgme.2014.12.026 - 发表时间:
2015-02-01 - 期刊:
- 影响因子:
- 作者:
David M. Bedwell;Dan Wang;Ellen M. Welch;Kim M. Keeling - 通讯作者:
Kim M. Keeling
David M. Bedwell的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('David M. Bedwell', 18)}}的其他基金
New Nonsense Suppression Drugs to Treat MPS I
治疗 MPS I 的新型无意义抑制药物
- 批准号:
8842247 - 财政年份:2014
- 资助金额:
$ 13.96万 - 项目类别:
Suppression of the Idua-W402X mutation in an MPS I-H mouse
MPS I-H 小鼠 Idua-W402X 突变的抑制
- 批准号:
7340377 - 财政年份:2007
- 资助金额:
$ 13.96万 - 项目类别:
Suppression of the Idua-W402X mutation in an MPS I-H mouse
MPS I-H 小鼠 Idua-W402X 突变的抑制
- 批准号:
8015606 - 财政年份:2007
- 资助金额:
$ 13.96万 - 项目类别:
UAB CF Research and Translation Core Center
UAB CF 研究与翻译核心中心
- 批准号:
10673353 - 财政年份:2007
- 资助金额:
$ 13.96万 - 项目类别:
Suppression of the Idua-W402X mutation in an MPS I-H mouse
MPS I-H 小鼠 Idua-W402X 突变的抑制
- 批准号:
7179609 - 财政年份:2007
- 资助金额:
$ 13.96万 - 项目类别:
Suppression of the Idua-W402X mutation in an MPS I-H mouse
MPS I-H 小鼠 Idua-W402X 突变的抑制
- 批准号:
7560341 - 财政年份:2007
- 资助金额:
$ 13.96万 - 项目类别:
UAB CF Research and Translation Core Center
UAB CF 研究与翻译核心中心
- 批准号:
10468801 - 财政年份:2007
- 资助金额:
$ 13.96万 - 项目类别:
相似海外基金
Toward a Political Theory of Bioethics: Participation, Representation, and Deliberation on Federal Bioethics Advisory Committees
迈向生命伦理学的政治理论:联邦生命伦理学咨询委员会的参与、代表和审议
- 批准号:
0451289 - 财政年份:2005
- 资助金额:
$ 13.96万 - 项目类别:
Standard Grant